Skip to main content

Mitchell Eric Horwitz

Professor of Medicine
Medicine, Hematologic Malignancies and Cellular Therapy
2400 Pratt St Suite 5000, DUMC Box 3961, Durham, NC 27710
2400 Pratt St Suite 5000, DUMC Box 3961, Durham, NC 27710

Overview


Allogeneic stem cell transplantation with a focus on the use of umbilical cord blood grafts; Allogenic stem cell transplantation for Sickle Cell Disease; Prevention of acute and chronic graft versus host disease; Improving immune recovery following alternative donor stem cell transplantation using donor graft manipulation.

Current Appointments & Affiliations


Professor of Medicine · 2016 - Present Medicine, Hematologic Malignancies and Cellular Therapy, Medicine
Member of the Duke Cancer Institute · 2003 - Present Duke Cancer Institute, Institutes and Centers
Affiliate of the Duke Regeneration Center · 2021 - Present Duke Regeneration Center, Basic Science Departments

In the News


Published May 17, 2023
More Options for People With Blood Cancer
Published December 5, 2018
Expanded Cord Blood Shows Potential for Use in Adult Bone Marrow Transplants

View All News

Recent Publications


Food insecurity prior to hematopoietic stem cell transplant is associated with malnutrition and worse outcomes.

Journal Article Bone Marrow Transplant · April 12, 2025 Food insecurity (FI), defined as the lack of continuous access to adequate food, affects 17-55% of cancer patients. Effects may be exacerbated in hematopoietic stem cell transplant (HSCT) patients, who face nutritional challenges due to treatment side effe ... Full text Link to item Cite

Omidubicel-onlv Transplantation for Hematologic Malignancies: Results of a Multicenter Expanded Access Program.

Journal Article Transplant Cell Ther · April 8, 2025 Omidubicel-onlv is an FDA-approved, nicotinamide-modified, allogeneic hematopoietic progenitor cell therapy derived from umbilical cord blood (UCB). A phase 3 study demonstrated improved hematopoietic recovery and decreased infections with omidubicel compa ... Full text Link to item Cite

Long-Term Toxicity after Non-Myeloablative Conditioning Regimens Using Total Body Irradiation.

Journal Article Adv Radiat Oncol · April 2025 PURPOSE: To evaluate long-term health risks after allogeneic hematopoietic stem cell transplantation (HSCT) using non-myeloablative total body irradiation (TBI). METHODS AND MATERIALS: All adult patients undergoing non-myeloablative allogeneic HSCT using T ... Full text Link to item Cite
View All Publications

Education, Training & Certifications


Rush University · 1992 M.D.